Six months to the day that the World Health Organization (WHO) declared it a public health emergency, the SARS-CoV-2 virus, with its hideous red spikes, continues to taunt the world, hopping from host to host and haunting humans, many of whom wonder the same thing: What’s next?
There were no surprises among the latest rankings in JLL’s Life Sciences Outlook report, which tracks geographic shifts in life sciences innovation, operations and facilities investments, and includes an analysis of markets actively investing in their life sciences sectors. Boston, San Francisco and San Diego once again occupied the top three spots as the leading U.S. life science clusters.
Biopharma companies that are focused on cell therapies have reported promising clinical trial results in their ability to treat acute respiratory distress syndrome (ARDS), a condition that has shown to be a significant contributor to higher mortality in COVID-19 cases.
The top two biggest money biopharma deals in 2020 occurred in June, putting the month ahead of all other months for the year in terms of deal values and volumes.
With an increasing number of neurological manifestations being reported in patients suffering from COVID-19 infection, the need for therapies to treat those conditions as well as other major CNS disorders has, once again, been highlighted. That may be one of the reasons why investors have turned their attention to the space once again, with several members of the BioWorld Neurological Diseases index enjoying an uptick in their share valuations.
RSS
